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Abstract
 
Here a new, intrinsically pluripotent, CD45-negative population from human cord blood,
termed unrestricted somatic stem cells (USSCs) is described. This rare population grows adher-
ently and can be expanded to 10
 
15
 
 cells without losing pluripotency. In vitro USSCs showed
homogeneous differentiation into osteoblasts, chondroblasts, adipocytes, and hematopoietic
and neural cells including astrocytes and neurons that express neurofilament, sodium channel
protein, and various neurotransmitter phenotypes. Stereotactic implantation of USSCs into intact
adult rat brain revealed that human Tau-positive cells persisted for up to 3 mo and showed
migratory activity and a typical neuron-like morphology. In vivo differentiation of USSCs
along mesodermal and endodermal pathways was demonstrated in animal models. Bony recon-
stitution was observed after transplantation of USSC-loaded calcium phosphate cylinders in
nude rat femurs. Chondrogenesis occurred after transplanting cell-loaded gelfoam sponges into
nude mice. Transplantation of USSCs in a noninjury model, the preimmune fetal sheep, resulted
in up to 5% human hematopoietic engraftment. More than 20% albumin-producing human
parenchymal hepatic cells with absence of cell fusion and substantial numbers of human car-
diomyocytes in both atria and ventricles of the sheep heart were detected many months after
USSC transplantation. No tumor formation was observed in any of these animals.
Key words: cord blood • regenerative medicine • ex vivo expansion • developmental potential
 
Introduction
 
Somatic human stem cells which can be propagated in
large quantities while retaining their ability to differentiate
into different tissue cell types could serve as a highly valuable
resource for the development of cellular therapeutics (1).
Although embryonic stem cells have the broadest differen-
tiation potential (2), their use for cellular therapeutics is
excluded for several reasons: the uncontrollable develop-
ment of teratomas in a syngeneic transplantation model
(3), imprinting-related developmental abnormalities (4), and
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
 
-glycerol phosphate; DAPI, 4-6
 

 
di-
amidino-2-phenylindoline
 
; 
 
GABA, gamma amino butyric acid; GFAP,
glial fibrillary acidic protein; hTau, human Tau protein; IBMX, isobuthyl
methyl xanthine; MAPC, multipotent adult progenitor cell; MSC, mes-
enchymal stem cells; NF, neurofilament; NGF, nerve growth factor;
NGS, normal goat serum; pd, population doubling; PFA, paraformalde-
hyde; TH, tyrosine-hydroxylase; USSC, unrestricted somatic stem cell.
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ethical issues (1). On the other hand, previously published
claims that adult tissue–specific stem cells possess an intrin-
sic differentiation potential to other tissues may have been
premature. Over the past years, studies have shown that af-
ter hematopoietic allo-transplantation with BM or G-CSF–
mobilized blood, a small percentage of donor cells can
also be detected as nonhematopoietic tissue (5–9). How-
ever, this so-called “plasticity” appears to be an ex-
tremely rare event and may not carry a physiologically rel-
evant impact in vivo (10). Moreover, subsequent data have
shown that certain results may be the result of cell fusion
(11). Recently, a rare cell from BM of rodents, called mul-
tipotent adult progenitor cell (MAPC), was identified
which differentiated in vitro into cells of all three germ lay-
ers and contributed to most somatic tissues when injected
into an early murine blastocyst (12). A phenotypically
identical cell was isolated from human BM (13). It is un-
clear, however, whether such MAPCs decline with donor
age, a phenomenon that has been observed for the he-
matopoietic (14) and the mesenchymal stem cell (MSC)
compartment from BM (15). In contrast to adult BM, the
stem cell compartment in cord blood (CB) is less mature.
This has been documented for the hematopoietic stem
cells, which in CB are more abundant than in BM and
have a higher proliferative potential associated with an ex-
tended life span and longer telomeres (16–19). Besides this
biological superiority, CB is abundantly available, is rou-
tinely harvested without risk to the donor, and infectious
agents such as CMV are rare exceptions (20)—a definite
advantage for the development of cell therapeutics in re-
generative medicine. We identified a rare, CD45 and HLA
class II–negative stem cell candidate displaying robust in
vitro proliferative capacity without spontaneous differenti-
ation but with intrinsic and directable potential to develop
into mesodermal, endodermal, and ectodermal cell fates.
Thus, we termed the primary population unrestricted so-
matic stem cell (USSC).
 
Materials and Methods
 
Generation and Expansion of USSCs.
 
CB was collected from
the umbilical cord vein with informed consent of the mother
(21). USSCs were generated from 94 (40.3%) of 233 CB. The
mononuclear cell fraction was obtained by Ficoll (Biochrom) gra-
dient separation followed by ammonium chloride lysis of RBCs.
Cells were plated out at 5–7 
 

 
 10
 
6
 
 cells/ml in T25 culture flasks
(Costar). Two different media were used to initiate growth of the
adherent USSC colonies: myelocult medium (StemCell Tech-
nologies) and low glucose DMEM (Cambrex) with 30% FCS,
dexamethasone (10
 

 
7 
 
M; Sigma-Aldrich), penicillin (100 U/ml;
Grünenthal), streptomycin (0.1 mg/ml; Hefa-pharma), and ultra-
glutamine (2 mM; Cambrex). Expansion of the cells was per-
formed in the same media but with a lower concentration or in
the absence of dexamethasone. Cells were incubated at 37
 

 
C in
5% CO
 
2
 
 in a humidified atmosphere. When cells reached 80%
confluency, they were detached with 0.25% trypsin (Cambrex)
and replated 1:3 as outlined in Table S1 available at http://
www.jem.org/cgi/content/full/jem.20040440/DC1. USSC karyo-
typing was performed by cytogenetic standard protocols.
 
Monoclonal Antibodies for Immunophenotyping of USSCs.
 
FITC-
conjugated Ab CD4 (13B8.2), CD8 (B9.11), CD11a (25.3.1),
CD14 (RMO52), CD15 (80h5), CD31 (5.6E), CD33
(D3HL60), CD34 (581), CD44 (J-173), CD62L (DREG56),
CD80 (MAB104), CD90 (F15.42), CD71 (YDJ122), HLA-ABC
(B9.12.1), F(ab
 

 
)2 goat anti–mouse IgM/IgG, and isotype con-
trols were from Beckman Coulter; CD45 (2D1), CD49b (AK7),
CD86 (FUN-1), and CD40 (5C3) were from BD Biosciences;
CD62E/P (1.2B6) were from Serotec; CD105 (SN6) was from
Caltag; and CD106 (BBIG-V3) was from R&D Systems. PE-
conjugated Ab CD11b (BEAR1), CD16 (3G8), CD25 (B1.49.9),
CD29 (K20), CD38 (T16), CD49e (SAM1), CD50 (HP2/19),
CD54 (84H10), CD56 (NKH-1), CD117 (95C3), and isotype
controls were from Coulter; glycophorin A (GA-R2), CD10
(HI10a), CD13 (L138), CD49d (L25.3), CD49f (GoH3), CD73
(AD2), CD123 (9F5), CD166 (3A6), and HLA -DR (G46-6)
were from BD Biosciences; and CD133/1 (AC133) and CD133/2
(AC141) were from Miltenyi Biotech. Unconjugated Ab CD58
(AICD58) and isotype controls from were Immunotech; FLK-1/
KDR (A-3), cytokeratin 8 (C51), cytokeratin 18 (DC-10), CK8/
18 (C51), and vimentin (V9) were from Santa Cruz; CD44H
(2C5) was from R&D Systems; and human endo (P1H12) was
from Chemicon. Goat anti–rat Cy2 and normal rat IgG were
from Dianova. Analysis was performed on a Beckman Coulter
EPICS XL-MCL.
 
RT-PCR Analysis of USSCs.
 
RT reactions were performed
at 50
 

 
C with Omniscript (QIAGEN) and the 3
 

 
 primers follow-
ing supplier’s instruction. The PCR reactions were performed
with HotStar Taq Master Mix (QIAGEN) at 93
 

 
C for 5 min,
35 
 

 
 93
 

 
C for 30 s, 55
 

 
C for 30 s, 72
 

 
C for 1 min, and 72
 

 
C for
5 min. Expression of the following molecules was detected by
RT-PCR: CD49e (5
 

 
-ggcttcaacttagacgcgg; 3
 

 
-ccaggttgatcagg-
tactc; 640 bp), CD105 (5
 

 
-cctgccactggacacagg; 3
 

 
-atggcagctctgtg-
gtgttg; 411 bp), CHAD (5
 

 
-aggaaccagctgtccagct; 3
 

 
-agtcaccaggac-
tggctg; 513 bp), PDGFRa (5
 

 
-acagtggagattacgaatgtg; 3
 

 
-cac-
atcagtggtgatctcag; 251 bp), EGFR (5
 

 
-tgccacaaccagtgtgct; 3
 

 
-gac-
cagttcatcagattcatc; 205 bp), IGFR (5
 

 
-cgagtggagaaatctgcgg; 3
 

 
-
gaccagggcgtagttgtag; 272 bp), RUNX1 (5
 

 
-gcaagctgaggagcggcg;
3
 

 
-gaccgacaaacctgaggtc; 296 bp), and GAPDH (5
 

 
-ctcaagatcat-
cagcaatgcc; 3
 

 
-gatggtacatgacaaggtgc; 755 bp).
 
Telomere Length Measurement.
 
Telomere length measurement
was performed with the Telo TAGGG Telomere Length Assay
(Roche Diagnostics) according to manufacturer’s instructions.
DNA was treated with RsaI and Hinfl. Detection was performed
with Image Master (Amersham Biosciences). Calculation of mean
telomere restriction fragment lengths (mean TRF) was performed
according to Harley et al. (22).
 
In Vitro Differentiation into Neural Cells.
 
USSCs were seeded
on glass coverslips coated with 1 mg/ml poly-
 
d
 
-lysine and
13 
 

 
g/ml laminin in differentiation medium XXL containing
DMEM, 15% heat-inactivated FCS, 100 U/ml penicillin/strep-
tomycin, 50 ng/ml nerve growth factor, 20 ng/ml bFGF, 1 mM
dibutyryl cAMP, 0.5 mM isobuthyl methyl xanthine (IBMX),
and 10 
 

 
M retinoic acid for up to 4 wk. For immunostaining,
cells were fixed for 15 min with 4% paraformaldehyde (PFA). For
immunostaining against gamma amino butyric acid (GABA) and
tyrosine-hydroxylase (TH), cells were fixed in 4% PFA, 0.3%
glutaraldehyde at RT for 5 min. After washing with PBS, cells
were incubated in 1 M ethanolamine at RT for 20 min, preincu-
bated and permeabilized in 10% normal goat serum with 0.03%
Triton X-100 for at least 30 min, followed by incubation with
the primary Ab (GABA 1:1000 (Sigma-Aldrich), TH 1:100
(Sigma-Aldrich), neurofilament 
 
(NF)
 
 cocktail 1:1,000 (BioTrend),
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DOPA-decarboxylase 1:500 (Sigma-Aldrich), glial fibrillary acidic
protein (GFAP) 1:300 (Chemicon), synaptophysin 1:100 (Sigma-
Aldrich), and Na
 

 
 channel 1:50 (Sigma-Aldrich). Secondary Ab
were anti–mouse-FITC (1:100; Southern Biotechnology) and
anti–rabbit rhodamine X Ab (1:1,000; Molecular Probes). Cell
nuclei were labeled with 4-6
 

 
diamidino-2-phenylindoline (DAPI;
Roche).
 
USSC Transplantation into the Hippocampus Region of Wistar
Rats.
 
USSCs were labeled with pKH26 (Sigma-Aldrich) ac-
cording to the supplier’s protocol 2 d before transplantation.
Adult male Wistar rats were anesthetized with Rompun (5 mg/
kg) (Bayer) and Ketavet (100 mg/kg) (Pharmacia Upjohn). For
transplantation, animals received a single, unilateral stereotactic
injection of 1 
 

 
l (75,000 USSC/
 

 
l) into the hippocampus region
using a 22-gauge needle. Coordinates were set according to the
atlas of Paxinos and Watson (23). The animals received immune
suppression by s.c. injection of cyclosporin A (15 mg/kg Sandim-
mune; Novartis) for 10 d, starting with a double dose injection
1 d before surgery. At different time points after transplantation
the animals were killed. The brains were immediately removed
and frozen in methyl butane (Sigma-Aldrich) on dry ice. 20-
 

 
m
coronal sections were cut through the brain using a freezing mi-
crotome (CM 3050; Leica). At intervals of 
 

 
400 
 

 
m, sections
were stained for human Tau protein (hTau). Sections were fixed
with 4% PFA for 10 min followed by 50%, 100%, 50% acetone
(Merck), each for 2 min. After a washing step, sections were
quenched by 0.3% H
 
2
 
O
 
2
 
 (Merck) for 30 min and blocked with
3% goat serum for 30 min. The hTau Ab (1:100; Chemicon) was
incubated overnight at 4
 

 
C. After washes with PBS, sections
were incubated with goat anti–rabbit biotinylated secondary Ab
(1:200; Vector) for 1 h and rinsed with PBS. Later, sections were
transferred to an avidin–biotin complex Vectastain ABC kit
(Vector) and were developed with 3,3-diaminobenzidine (DAB;
Sigma-Aldrich) and H
 
2
 
O
 
2
 
 for 10 min, dehydrated, and mounted
in Entellan (Merck).
 
In Vitro Differentiation into Osteoblasts, Chondroblasts, and Adipo-
cytes.
 
For differentiation into osteoblasts, USSCs were plated at
8,000 cells/cm
 
2
 
 in 24-well plates and at 70% confluency supple-
mented with 10
 

 
7 
 
M dexamethasone, 50 
 

 
M ascorbic acid-2
phosphate, and 10 mM dexomethasone, asorbic acid, 
 

 
-glycerol
phosphate (DAG) (24). For Alizarin red staining, cells were fixed
for 5 min with 70% ethanol at 4
 

 
C to determine calcium deposi-
tion. Alkaline phosphatase (ALP) activity was determined in cell
lysates obtained by treating cell cultures with 1% Triton X-100.
The ELISA-based method was performed according to the man-
ufacturer’s protocol (Sigma-Aldrich). Results are expressed in
nmol of p-nitrophenol produced per min. For quantitative Ca
 
2
 

 
determination, cell layers were scraped off the dish in 0.5 N HCl
according to manufacturer’s instructions (Sigma-Aldrich). For
chondrogenic differentiation, a micromass culture system was
used (25). 2 
 

 
 10
 
5
 
 USSCs were cultured in DMEM high glucose
supplemented with antibiotic, 100 nM dexamethasone, 35 
 

 
g/ml
ascorbic acid-2-phosphate, 1 mM sodium pyruvate, ITS 
 

 
 pre-
mix (1:100 dilution), and 10 ng/ml TGF
 

 
1. Aliquots of 2 
 

 
 10
 
5
 
cells in 0.5 ml of medium were centrifuged at 150 
 
g
 
 in 15 ml
polypropylene conical tubes. The pelleted cells were incubated at
37
 

 
C and 5% CO
 
2
 
 for 21 d. For Alcian blue staining, cell aggre-
gates were fixed in 4% formalin and cut into 10-
 

 
m sections and
stained for histology. For immunostaining, frozen sections were
fixed with 100% ethanol, incubated in 0.2 U/ml chondrotinase
ABC for 40 min at 37
 

 
C. Blocking of nonspecific Ab binding
sites was performed in 5% BSA/PBS for 1 h. The sections were
incubated with the primary Ab diluted in 0.5% BSA/PBS for 1 h.
Collagen type II (Chemicon) was detected by fluorescence mi-
croscopy after incubation for 30 min with a FITC-labeled sec-
ondary Ab diluted in 0.5% BSA/PBS. To induce differentiation
into adipocytes, cells were plated at 1,000 cells/cm
 
2
 
 in 24-well
plates in DMEM with 1 
 

 
M dexamethasone (Sigma-Aldrich), 10
 

 
g/ml insulin, 0.5 mM IBMX (Sigma-Aldrich), and 100 
 

 
M in-
domethacin (Sigma-Aldrich) (26). After 2 wk of adipogenic stim-
ulation, cells were fixed in 5% PFA for 30 min and incubated
with Oil Red-O to stain lipid vacuoles.
 
In Vivo Differentiation into Bone and Cartilage.
 
The surgical
details of the femoral gap bone repair model were performed ac-
cording to a method described by Bruder et al. (27), and differen-
tiation into cartilage was shown previously (28).
 
In Vitro Differentiation into Hematopoietic Cells.
 
10
 
5
 
 USSCs
were expanded for 2 wk with 100 ng/ml Flt3-L (CellGenix), 100
ng/ml SCF (CellGenix), 100 ng/ml IL-3 (Cellsystems), 100 ng/
ml IL-6 (CellSystems), 100 ng/ml TPO (CellGenix), and 100
ng/ml G-CSF (Amgen) in Myelocult medium as described previ-
ously (29). Human CFU assays were performed on days 0 and 14
(29) with 10
 
4
 
 cells in Methocult (Stem Cell Technologies).
 
Detection of In Vivo Differentiation into Heart and Liver.
 
Sheep
heart was dissected into right and left atria, right and left ventri-
cles, and septum. Several random strips from each area were fixed
in 4% PFA, cut into 1 
 

 
 1-mm cubes, and embedded in OCT
medium. 7–10-
 

 
m cryosections were probed with a human-spe-
cific anti–heat shock protein 27 (HSP27) Ab (Stressgen) (30) or
the antidystrophin Ab NCL DYS2 (Novocastra) and anti–protein
gene product 9.5 (PGP 9.5, ubiquitin c terminal hydroxylase)
(Biogenesis). The secondary Ab for anti-HSP27 and antidystro-
phin was goat anti–mouse conjugated to Alexa 488, and the sec-
ondary Ab for anti-PGP 9.5 was goat anti–rabbit conjugated to
Alexa 647 (Molecular Probes). Livers of the sheep were fixed in
buffered formalin and embedded in paraffin. Liver sections (2
 

 
m) were dewaxed and incubated for 10 min at 90
 

 
C for target
retrieval. After blocking endogenous peroxidase by EnVision
blocking reagent (Dako), sections were incubated in serum-free
protein block (Dako) for 10 min and for 2 h in TBS containing
0.1% gelatin and the primary Ab anti–human serum albumin
(clone HSA-11; 1:100; Sigma-Aldrich) or monoclonal anti–
human hepatocyte Ab (clone OCH1E5; Dako). After washing, sec-
tions were incubated for 30 min with labeled polymer (EnVision
System; Dako), and immunoreactivity was visualized by in-
cubation with diaminobenzidine tetrahydrochloride. For micro-
dissection applying the PALM Micro Beam System, immuno-
histochemistry was performed as described above with the
monoclonal anti–human hepatocyte, clone OCH1E5 Ab except
that sections were mounted on foil-laminated glass slides.
 
Single Cell PCR Analysis of Fusion/Cell Hybrids. Isolation of
single cells of human origin from human and sheep chimera liver
tissue sections with 	20% human cells and single cells of ovine
origin from chimera liver tissue sections were performed using the
PALM Micro Beam System (P.A.L.M. Microlaser Technologies).
After target cell identification (the chimeric sheep liver slides were
stained previously with the human hepatocyte specific Ab) and
dissection from the surrounding tissue by a nitrogen laser beam
(LMM), another strong laser was used to catapult (LPC) the mi-
crodissected material directly into the tube cap containing 20 l of
PCR buffer (Promega). Before PCR amplifications, cells were di-
gested by proteinase K as described (31). To analyze individual
micromanipulated parenchymal liver cells from human liver and
human (stained) and ovine (unstained) cells from chimeric sheep
liver tissue, genomic fragments of the human VH1, ovine VH7 and
human TCRV7.2 and ovine TCRC
 genes were amplified
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with all external primer pairs in a first PCR round. 1-l aliquots
from the first amplification round were then subjected to a second
round of fully nested PCR amplification using internal PCR
primers. The sequences of the primers used for PCR amplification
are given in Table S2, available at http://www.jem.org/cgi/
content/full/jem.20040440/DC1. Single-cell PCR amplifications
were performed in a 60-l reaction mix volume containing 2.5
mM MgCl2 [Promega], 200 M of each dNTP, 2.5 M of each
primer, 1 PCR buffer [Promega], and 2.5 U platinum Taq-
polymerase (Invitrogen). Cycling conditions for the first round in-
cluded a single 2-min denaturation step at 95C followed by 34
cycles at 95C for 1 min, 56C for 30 s, and 72C for 1 min, and a
5-min incubation at 72C. For the second PCR round, 45 cycles
of amplification were used. To rule out interspecies cross-reactiv-
ity of the primer pairs used, we also amplified DNA from ovine
cells with human-specific primers and vice versa. Amplification
products were analyzed by agarose gel electrophoresis.
Western Blot for Human Albumin. Serum proteins (human 50
ng/lane, ovine 500 ng/lane) were separated on a 12% SDS-poly-
acrylamide gel. After tank blotting onto a nitrocellulose mem-
brane (Amersham Biosciences), blots were blocked with 5%
blocking-grade nonfat dry milk (Amersham Biosciences) in PBS
containing 0.05% Tween (PBS-T), incubated at 4C for 12 h
with a human albumin-specific Ab (HAS-11, 1:5,000; Sigma-
Aldrich). After five washes for 5 min in PBS-T, blots were incu-
bated with horseradish peroxidase–coupled anti–mouse secondary
Ab (1:2,000; Amersham Biosciences) at RT for 1 h. Membranes
were washed again and developed using the Amersham Bio-
sciences ECL system according to manufacturer’s instructions.
Online Supplemental Material. Expansion kinetic of USSCs
(cell numbers, passages, and population doublings) are shown in Ta-
ble S1. The sequences of the primers used for PCR amplification in
the single cell PCR analysis of fusion/cell hybrids of the chimeric
liver tissue are given in Table S2. Tables S1 and S2 are available at
http://www.jem.org/cgi/content/full/jem.20040440/DC1.
Results
Isolation, Expansion, and Characterization of USSCs from
Placental CB. USSCs were generated from 94 CB samples
of a mean gestational age of 39.5  1.46 wk (range 34–42),
a net volume of 80  21.4 ml including 29 ml citrate-phos-
phate dextrose (range 43–140 ml) and a total nucleated cell
count of 7.6  3.1  108 (range 2.4–19.4). No correlation
was detected between gestational age (	30 wk), hours
elapsed after CB collection, volume, number of mononuclear
cells in the CB after gradient separation and the success in
generation of USSC. After 6–25 d (mean 15 d), adherently
growing cells (USSC colonies) of fibroblastic morphology
were detected with a median frequency of four colonies per
Figure 1. Characteristics of USSCs. (A) Spindle-shaped USSCs plated
at low density after 32 population doublings (20 magnification). (B) USSCs
plated at high density after 24 population doublings (20 magnification).
(C) Immunophenotype of USSCs. Cells were labeled with the mAb spe-
cific for the molecules indicated (open histograms) or isotype controls
(filled histograms). (D) Expansion kinetics of USSCs for 20 passages (p)
equivalent to 46 population doublings (pd). (E) Expanded USSCs from
CB have longer telomeres than MSCs from BM. Lane 1, ladder; lane 2,
MSCs from BM, 19 pd (p4); lane 3, MSCs from BM, 27 pd (p9); lane 4,
USSCs from CB, 21 pd (p4), lane 5, USSCs from CB, 25 pd (p9); lane 6,
USSCs from CB, 36 pd (p13); lane 7 and 8, controls. Low weight (lw)
and high weight (hw) telomeres were used according to manufacturer’s
instructions. (F) RT-PCR from undifferentiated USSCs: lane1, EGFR
(205 bp); lane 2, IGFR (272 bp); lane 3, RUNX1 (296 bp); lane 4,
CD105 (499 bp); lane 5, CD49e (640 bp); lane 6, CHAD (513 bp); lane 7,
PDGFRa (251 bp). All reactions were coamplified with GAPDH (755 bp)
as an internal positive control. All of these genes were expressed except
for chondroadherin.
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CB (range 1–11). As shown in Fig. 1, A and B, USSCs are
adherent, spindle-shaped cells, and have a size of 20–25 m.
Hematopoietic CD45 cells were no longer detected after
three passages. The USSC karyotype was normal 46XX or
46XY as analyzed for six individual USSC specimens for
passages 5 (21 population doublings) to 19 (45 population
doublings). USSCs were negative for CD14, CD33, CD34,
CD45, CD49b, CD49c, CD49d, CD49f, CD50, CD62E,
CD62L, CD62P, CD106, CD117, glycophorin A, and
HLA-DR and expressed high levels of CD13, CD29,
CD44, CD49e, CD90, CD105, vimentin, and cytokeratin
8 and 18, human Endo, low levels of CD10, and FLK1
(KDR), and showed variable but weak expression of HLA-
ABC (Fig. 1 C). USSCs can be cultured for 	20 passages
equivalent to 	40 population doublings without any spon-
taneous differentiation (Fig. 1 D and Table S1). The average
telomere length of USSCs obtained after both 21 (passage 4)
and 25 population doublings (passage 6) was 8.93 kbp; after
36 population doublings, the average telomere length of
USSCs obtained was 8.60 kbp (passage 13). This is signifi-
cantly longer than the telomere length of MSCs generated
from a BM donor (age 30 yr) with 7.27 (passage 4) and 7.11
kbp (passage 9) at 19 and 27 population doublings, respec-
tively (Fig. 1 E). USSCs showed expression of transcripts for
epidermal growth factor receptor, platelet-derived growth
factor receptor, insulin-like growth factor receptor, runt
related transcription factor (Runx1), YB1, CD49e, and
CD105 (Fig. 1 F). They were negative for the chondro-
genic extracellular protein chondroadherin (Fig. 1 F), the
bone-specific markers collagenase X, bone sialoprotein, the
liver and pancreas-specific markers Cyp1A1 and PDX-1,
and neural markers such as NF, synaptophysin, TH, and
glial fibrillary acid protein (not depicted). Preliminary cDNA
microarray analysis performed for two individual USSCs
and one MSC preparation from human BM suggested dif-
ferential expression of HAS1, which was only detected in
MSCs but not in USSCs. This differential expression of
HAS1 was confirmed by RT-PCR (n  55; unpublished
data) and immunochemistry.
Differentiation into Neural Cells In Vitro and In Vivo. In-
dividual USSC preparations (n  10) from passages 3–16
were analyzed for their neural differentiation potential. In
XXL medium, the number of NF-positive cells increased,
starting with 30% after 1 wk to more than 70% homoge-
neity after 4 wk (Fig. 2 A). Double immunostaining re-
vealed colocalization of NF and sodium-channel protein in
a small proportion of cells (Fig. 2 B). Expression of synapto-
physin was detected after 4 wk (Fig. 2 C), indicating a more
mature phenotype of neurons. Consistently, 90% of the
cells stained positive for the inhibitory neurotransmitter
GABA (Fig. 2 D). USSC-derived neurons could be identi-
fied that stained positive for TH (30% of the cells), the
key enzyme of the dopaminergic pathway (Fig. 2 E). On
Figure 2. In vitro and in vivo differentiation of USSCs into neural
cells. In XXL, medium differentiated cells showed positive immunoreactivity
for the neuron-specific marker NF (A), voltage-gated sodium channels
(green) coexpressed with NF (red) (B) for synaptophysin, a protein located
in the synaptic vesicles of neurons (C), the inhibitory neurotransmitter
GABA (D), the enzymes TH (E), DOPA-decarboxylase (F), and choline
acetyltransferase, the enzyme of the cholinergic pathway (G), and the
astrocyte-specific marker GFAP (H). Cell nuclei show a blue color due to
DAPI staining. USSCs staining positively for hTau in the ipsilateral cor-
tex 3 mo after stereotactic implantation into the hippocampus region (I).
Note the long processes (indicated by arrowheads) and the highly differ-
entiated neuronal like morphology. Bars, 100 m.
Pluripotent Somatic Cells from Placental Cord Blood128
the other hand, the number of DDCs (Fig. 2 F), the subse-
quent enzyme of the same transmitter pathway, was highly
variable. Choline acetyltransferase, the enzyme of the cho-
linergic pathway, was detected in 50% of the cells (Fig. 2
G). Since 90% of USSCs in vitro showed positive immu-
noreactivity for GABA, coexpression with the enzymes of
other neurotransmitter pathways was observed. These find-
ings could be explained by the function of GABA during
very early embryogenesis, where it is described to act as a
signal molecule in neuronal development (32). Extensive
analyses by patch-clamp recording of different USSC
batches did not thus far reveal a voltage-activated, fast inac-
tivating Na current, which is typical of terminally differen-
tiated neurons (Copi, A., and K. Gottmann, personal com-
munication). This finding suggests that USSCs differentiate
to a precursor-like phenotype in vitro, in which distinct
neuron-specific proteins are expressed, but a fully functional
neuronal phenotype has not yet developed. Moreover,
USSCs differentiated into astrocytes expressing GFAP, an
astroglial intermediate filament reaching a transient maxi-
mum level of 45% at 2–3 wk in XXL medium (Fig. 2 H).
During early differentiation, coexpression of GFAP and NF
could be observed, indicating a common progenitor cell
type (unpublished data). Interestingly, after 2–3-wk GFAP
immune reactivity declined resulting in a more enriched
neuronal cell population. To analyze the potency of USSCs
to migrate, integrate, and differentiate into neuronal-like
cells in vivo, USSCs were labeled with pKH26 and trans-
planted stereotactically into the hippocampus region of an
intact adult rat brain. Numerous pKH26-labeled cells could
be detected after 3 mo postgrafting (unpublished data). At 3
mo postimplantation, USSCs expressing human Tau pro-
tein could be identified widely distributed throughout the
brain, indicating a high migratory activity of USSCs in vivo.
Figure 3. In vitro and in vivo differentiation of USSCs into osteoblasts,
chondroblasts, and adipocytes. (A) Differentiation to osteoblasts is shown
by the ALP assay. The peak of ALP was already achieved on day 7. Both
basic media McCoy (filled square) and DMEM (filled triangle) in the
presence of DAG were able to support the osteoblast differentiation.
USSCs (control: open triangle, DMEM; open square, McCoy) cultured
without DAG showed no ALP activity. (B) Quantitative Ca2 release assay.
Both basic media McCoy (filled square) and DMEM in the presence of
DAG (filled triangle) were able to support the osteoblast differentiation.
USSCs (control: open triangle: DMEM; open square, McCoy) cultured
without DAG showed no Ca2 activity. (C and D) Chondrogenic differ-
entiation. (C) Demonstrates an Alcian blue–positive extracellular matrix
at day 21 after stimulation toward the chondrogenic pathway, indicating a
homogeneous distribution of sulfated proteoglycans within the matrix
structure (10 magnification). (D) Collagen type II staining of pellet micro-
sections analyzed by fluorescence microscopy; the nuclei are stained with
DAPI (40 magnification). (E) Oil Red-O staining of the lipid vesicles
performed 2 wk after stimulation demonstrates an ongoing adipogenesis
(40 magnification). In vivo differentiation of USSCs into bone and car-
tilage. (F–M) Ceramic cylinders were loaded with USSCs and trans-
planted into nude rat femur critical size defects of 0.5 cm in length. (F) 4
wk after transplantation, human cells were still present in the bone defect
as demonstrated by immunohistochemical staining with the human-specific
mAb 6E2 (20 magnification). (G and H) Images of the longitudinal (G)
and cross section (H) demonstrate bony healing between the cell-loaded
implant and the host bone (HB). Bony integration was established in
forms of cancellous bone as detected by Toluidine blue staining (4 mag-
nification). (I) Faxitron high resolution x-ray scanning of specimens harvested
at 12 wk after surgery demonstrates the healing between the cell-loaded
implant and the host bone (magnification, original size). (J) Unloaded ceramic
cylinders served as negative controls demonstrating a nonhealing between
the scaffold and the host bone. Arrows indicate the interface between the
scaffold and the host bone (magnification, original size). (K–M) A successful
in vivo chondrogenesis of USSC-loaded Gelfoam sponges in a nude
mouse model. Human USSCs loaded into gelatin sponges were cultured
in vitro for 1 (K) or 2 (L) wk in a chondrogenic medium with TGF-.
These sponges were s.c. implanted into nude mice for another 3 wk before
analysis. At 1 (K) or 2 (L) wk of in vitro culture, cells filled the pores of
the Gelfoam sponge. Some local spots demonstrate an extracellular matrix
formation which indicate chondrogenic lineage differentiation. The im-
planted cells demonstrate strong chondrogenic differentiation as docu-
mented by Toluidine blue staining (M) (10 magnification).
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Human Tau immune staining further revealed the neu-
ronal-like, highly differentiated morphology of implanted
USSCs in different ipsi- and contralateral regions of the
adult brain including the neocortex (Fig. 2 I). In the brain
of a nongrafted control animal, no human Tau immunore-
activity could be detected (unpublished data).
In Vitro Differentiation of USSCs into Bone, Cartilage, and
Adipocytes. All USSCs tested (n  30; up to passage 21)
were capable of differentiating along the osteogenic and
chondrogenic lineage. Adipogenic differentiation was ob-
served for all six USSCs tested. Differentiation into osteo-
blasts was induced by dexamethasone, ascorbic acid, and
DAG. After 5 d, cells showed initial calcium phosphate de-
posits. Bone-specific ALP activity was detected (Fig. 3 A)
and continuous increase in Ca2 release was documented
(Fig. 3 B). Osteogenic differentiation was confirmed by ex-
pression of ALP, osteocalcin, osteopontin, bone sialo-pro-
tein, and collagen type I detected by RT-PCR (unpub-
lished data). A pellet culture technique was employed to
trigger USSCs toward the chondrogenic lineage (25). The
chondrogenic nature of differentiated cells was assessed by
Alcian blue staining (Fig. 3 C) and by expression of the car-
tilage extracellular protein type II collagen (Fig. 3 D).
Chondrogenesis was further confirmed by RT-PCR for
the cartilage-specific mRNAs encoding Cart-1, collagen
type II, and chondroadherin (unpublished data). For induc-
tion of adipogenic differentiation, USSCs were cultured
with dexamethasone, insulin, IBMX, and indomethacin
(26). Adipogenic differentiation was demonstrated by Oil
Red-O staining of intracellular lipid vacuoles (Fig. 3 E).
In Vivo Differentiation of USSCs into Bone and Cartilage.
To determine the in vivo regeneration capacity for bone,
the repair of critical size bone defects with USSC-loaded
calcium phosphate ceramic cylinders was demonstrated.
USSCs (n  7) were expanded to passage 5 and loaded into
porous ceramic cylinders of 5-mm length before implanta-
tion into the femur critical size bone defect of athymic
Harlan Nude rats. 4 wk after transplantation, human cells
were still alive within the defect bone (Fig. 3 F). Images of
longitudinal (Fig. 3 G) and cross sections (Fig. 3 H) dem-
onstrated bony healing between the cell-loaded implant
and the host bone. Bony integration was established in
forms of cancellous bone as detected by Toluidine blue
staining. After 12 wk, a clear bony reconstitution was ob-
served (Fig. 3 I). Cell-free implants served as negative con-
trols (Fig. 3 J). However, it is impossible to quantitatively
assess the number of human cells in the responding zone,
since serial section reconstruction was not performed.
Moreover, as shown by Allay et al. (33) the human cells
initiate the fabrication of lamellar bone in implanted ce-
ramic vehicles, but since the osteoblasts half-lives are 8–10 d,
eventually the momentum of bone formation is joined by
host-derived cells. However, the observation shown here
indicates that the USSCs initiated the bone formation in
the orthotopic site. The in vivo chondrogenic potential
was assayed by loading USSCs into gelatin sponges (4  4
mm, Gelfoam®; Upjohn Pharmacia). They were cultured
in chondrogenic medium with supplementation of TGF-
(5 ng/ml) for up to 2 wk (Fig. 3, K and L) and then im-
planted s.c. into nude mice. After an additional 3 wk, the
implanted cells demonstrated strong chondrogenic differ-
entiation as shown by Toluidine blue staining (Fig. 3 M).
In Vivo and In Vitro Differentiation of USSCs into Hemato-
poietic Cells. To evaluate the potential of USSCs to differ-
entiate in vivo into hematopoietic cells, in utero transplan-
tation into fetal sheep was employed (34). USSCs were
transplanted intrauterine before immunological maturity.
USSCs originating from one expanded colony tested nega-
tive for the human hematopoietic antigen CD45 by flow
cytometry and PCR and were injected i.p. (1,500 USSC/
sheep) into six preimmune (day 57–62) fetal sheep. To de-
termine donor cell engraftment, blood and BM cells were
analyzed by flow cytometry for the presence of human cells
as described previously (35). Multilineage hematopoietic
engraftment was observed, which included cells of erythroid
(glycophorin A), myeloid (CD13, CD33), and lymphoid
(CD3, CD7, CD10, CD20) lineages. Four out of six ani-
mals showed clear evidence of human hematopoietic recon-
stitution (up to 5% human hematopoietic and lymphopoi-
etic engraftment in the total nucleated cell fraction in the
blood after RBC lysis) 4-mo posttransplantation (Table I).
The level of these human cells in the BM of these sheep was
maintained through 12 mo posttransplant. In an attempt to
elucidate these primarily unexpected in vivo results in vitro,
104 and 105 USSCs (n  14; passages 5–8) were plated di-
rectly into a standard CFC assay. However, immediate he-
matopoietic colony formation was not observed for any of
the 14 USSC preparations. When 105 USSCs (n  14) were
cultured for 2 wk in the presence of hematopoietic growth
factors, the cell number decreased to 3  104 cells (range
2.0–3.4  104). When these growth factor pretreated cells
were subjected to the same standard CFC assay with 104 to-
tal cells, in 2 of 14 USSC preparations hematopoietic CFC
were observed, but the frequency of two and six colonies
per 104 seeded USSCs was very low. Since the morphology
of such CFC was slightly different than that of regular CFC
in CB or BM, the USSC-derived CFCs were pooled and
analyzed by flow cytometry. The expression of glycophorin
A (Fig. 4, 2.7%) and CD33 (Fig. 4, 85%) on these colony-
derived cells confirmed the hematopoietic nature.
In Vivo Differentiation of USSCs into Myocardial Cells and
Purkinje Fibers. To explore the in vivo differentiation po-
tential of USSCs into myocardial cells, the preimmune fe-
Figure 4. In vitro hematopoie-
sis of USSCs. Glycophorin A (PE-
conjugated Ab) staining of the
colonies for confirmation of ery-
throid progenitor cells and CD33
staining (FITC-conjugated Ab) of
the colonies for the detection of
myeloid progenitor cells. mAb
specific for the molecule indicated
(open histograms) or isotype con-
trols (filled histograms).
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tal sheep model was applied as described above. Differenti-
ation of USSCs into human cardiomyocytes was analyzed
8 mo after transplantation. We have demonstrated previ-
ously the strict human specificity of the anti-HSP27 in
sheep heart (30). Positive staining with the human-specific
anti-HSP27 Ab was found in both atria, both ventricles,
and the septum of the heart of in utero USSC-transplanted
sheep, indicating that in this developmental in vivo model
USSCs can robustly engraft throughout the heart (Fig. 5,
A and B). Within the cells displayed in the longitudinal
tissue section (Fig. 5 A), the HSP27 staining shows a
striped pattern, which is consistent with previous findings
(36). To demonstrate that the cells labeled with the hu-
man-specific HSP27 Ab were mature cardiomyocytes, tis-
sue sections were probed with several antibodies that have
a distinctive staining in cardiac cells. These antibodies em-
ployed had a broad specificity so that they could be used to
confirm that this staining pattern was identical for the cells
derived from the USSCs and from the surrounding cardiac
sheep cells. Antibodies included antiryanodine receptor,
anti-MHC, and as shown in Fig. 5, C and D, antidystro-
phin. In the adult heart, dystrophin is expressed at signifi-
cant levels and localized at the plasma membrane (37, 38).
As can be seen, both engrafted human cells and sheep cells
have the mature pattern of distribution of dystrophin and
are indistinguishable. The distribution pattern of HSP27
(Fig. 5 A) and other proteins such as dystrophin (Fig. 5, C
and D) indicate that the engrafted human cells have a ma-
ture cardiac phenotype and the correct localization of pro-
teins to be functional cardiomyocytes. The distribution
of the engrafted cells observed was not homogeneous
throughout the heart. In certain areas only single HSP-27–
positive cardiomyocytes were detected, whereas in other
areas groups of positive human cardiomyocytes were in-
terspersed with sheep cardiomyocytes (Fig. 5 E). In some
areas the engrafted cells were found in patches, with 10–
20% of the cells in these areas being human cardiomyo-
cytes interspersed with sheep cardiomyocytes. These quan-
tities ranged from 0–3% of the sections analyzed (n  30);
however, in the atria and ventricle-positive patches of up
to 10–20% USSC-derived cells were found. There was
no pattern in the distribution, such as proximity to blood
vessels. Using the preimmune fetal sheep model, we had
shown previously that human MSCs from both fetal and
adult sources engraft predominantly in the Purkinje fiber
system and there are very few human cardiomyocytes (30).
In this study, engraftment of USSCs in the Purkinje fiber
system was detected also. Identification was by the charac-
teristic morphology and staining with the characteristic
Purkinje fiber marker PGP 9.5 (30). Similar to our earlier
demonstration in preimmune sheep injected with human
MSC, the engrafted human cells derived from USSCs
were found in aggregates (Fig. 5 F) and not interspersed
with sheep Purkinje fiber cells. This result is in contrast to
the engrafted human cardiomyocytes, which are inter-
spersed with the sheep cardiomyocytes.
In Vivo Differentiation of USSCs into Hepatic Cells. To
examine human hepatocyte development, livers of the
sheep were taken 14-mo post-USSC transplantation. Fig. 6
A shows the specific staining of the human hepatocyte Ab
OCH1E5 with a human liver. A liver from a nontrans-
planted sheep showed no cross-reactivity with the human-
specific Ab (Fig. 6 D). As shown in Fig. 6 C in close associ-
ation with portal veins, donor parenchymal liver cells
generated from the USSCs represent the majority of total
hepatic cells. Counting of representative areas of tissue sec-
tions of chimeric sheep liver revealed that 21.1  3.2% of
total liver cells were stained positive by the Ab that specifi-
Table I. Hematopoietic Cell Chimerism After Human USSC in Utero Transplantation into Fetal Sheep
Antibody
Blood 
4 moa post-TPX
Bone marrow 
4 moa post-TPX
Bone marrow 
5 mob post-TPX
Bone marrow 
12 mob post-TPX
CD45 1.66 (0.06–4.68) 0.09 (0.06–0.12)  1.42 (1.10–1.90)  2.75 (1.80–4.20)
CD34 0.00 (0.00–0.00) 0.14 (0.00–0.40) 0.09 (0.07–0.14) 0.18 (0.13–0.20)
Glycophorin A 4.45 (2.63–6.50) 2.26 (1.72–2.67)  3.02 (1.20–5.20)  2.30 (0.00–4.20)
CD7 0.59 (0.41–0.78) 2.23 (0.95–4.04)  1.85 (0.90–3.00)  2.70 (1.10–4.90)
CD3 0.44 (0.00–0.89) 0.29 (0.00–0.89) 0.37 (0.00–0.90) 1.08 (0.90–1.30)
HLA-DR 3.07 (0.67–6.68) 0.35 (0.00–1.05) ND ND
CD10 0.15 (0.08–0.29) 0.06 (0.00–0.14) ND ND
CD33 0.00 (0.00–0.00) 0.01 (0.00–0.04) ND 0.70 (0.00–1.40)
CD13 0.06 (0.00–0.15) 0.01 (0.00–0.02) ND ND
CD20 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.15 (0.00–0.30) 0.52 (0.00–0.60)
Each fetus was transplanted with 1,500 cells. Please note that the values for some markers together (HLA-DR; CD7, CD3) exceed those of CD45.
The up and down regulation of CD45 on different cell populations in this xenogeneic model was described previously (49). ND, not done.
an  3 animals were analyzed; mean (range) values in percentages are presented.
bn  4 animals were analyzed; mean values in percentages are presented.
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cally recognizes human hepatocytes in association with por-
tal veins 	80%. To use a different human-specific Ab, the
mAb HSA-11 recognizing human albumin was applied,
which shows a specific staining for the human liver (Fig. 6
E) and no reactivity with the sheep liver (Fig. 6 H). In con-
trast, the liver of the sheep transplanted with USSCs showed
a strong staining with human albumin (Fig. 6 G). Since hu-
man albumin is a secreted protein, the majority of cells
stained positive, some showed a very strong pattern of albu-
min distribution, and the ones in the periphery showed a
weaker staining. Fig. 6 I reproduces a Western blot showing
Figure 6. In vivo differentiation of USSCs from CB into parenchy-
mal liver cells in the preimmune fetal sheep model. (A) Positive con-
trol: human liver stained with the anti–human hepatocyte Ab. The
specificity for parenchymal liver cells is shown, since fibroblasts and en-
dothelial cells in association with the portal spaces are negative. (B) Nega-
tive control: human liver stained with only the second Ab; no reaction
or unspecific staining was observed. (C) Photomicrographs show the
staining for the anti–human hepatocyte Ab in liver sections of animals
transplanted with USSCs; in close association with the portal veins
	80% of cells stained positive. No vessels are stained. (D) Negative
control: the liver of a normal sheep shows no reaction with the Ab spe-
cific for human hepatocytes (A–D,  20 magnification). (E–H) The
anti–human albumin staining of the liver. E is the positive control: the
human liver stained positive with the mAb HSA-11. (F) The human
liver stained with only the second Ab: no reaction or unspecific stain-
ing was observed. (G) The staining of the anti–human albumin Ab in
liver sections of animals transplanted with USSCs. (H) Liver of a nor-
mal sheep showed no reaction with the human albumin. (E–H, 20
magnification). (I) Western blot of human albumin in human serum
and serum of chimeric and control sheep. A representative Western
blot is shown.
Figure 5. In vivo differentiation of USSCs to cardiomyocytes and
Purkinje fibers. (A and B) Groups of engrafted cells in the right atria in a
longitudinal section (A) and from the right ventricle in a cross section (B)
stained with human-specific anti-HSP27. (C and D) Serial sections of the
right ventricle. C is labeled with a human-specific anti-HSP27 mAb, and
D is labeled with an antidystrophin mAb with broad species specificity.
Arrows indicate the same cells. (E) An area from the left ventricle showing
areas of engrafted human cells surrounded by sheep cells. (F) A section of
Purkinje fiber labeled with the human-specific anti-HSP27. Bars: (A–E)
50 m; (F) 100 m.
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a specific human albumin band and thus the functional pro-
duction of this human protein in vivo in serum of the sheep
obtained 17 mo after transplantation of the USSCs in utero.
Cell Fusion Does Not Account for Liver Cell–specific Differen-
tiation of USSC. To determine whether the human cells
integrated into the sheep liver parenchyma acquired an or-
gan-specific differentiated phenotype through cell fusion
with indigenous ovine liver parenchymal cells or by liver
cell differentiation, we tested single microdissected liver pa-
renchymal cells from chimeric liver tissue for the coexist-
ence of human and ovine genomes in these cells. To this
end, single liver parenchymal cells, in which either expres-
sion of human proteins could be detected or were devoid
of human proteins, were micromanipulated from chimeric
liver sections and separately analyzed by single cell PCR.
Each cell was transferred into a PCR reaction tube, di-
gested by proteinase K, and subjected to two rounds of
nested PCR amplification using four sets of human and
sheep DNA–specific primers. To check for potential inter-
species cross-reactivity of these primer sets specific for IGH
and TCR loci of either human or sheep origin, we micro-
dissected single liver parenchymal cells from human liver
tissue sections as a control. From one third of the microdis-
sected cells, we obtained a human PCR product but not a
single PCR product of sheep origin. While analyzing 80
cells from chimeric tissue prestained with the human hepa-
tocyte-specific Ab OCH1E5, human DNA fragments orig-
inating from the human IGH or TCRB loci and sheep
DNA fragments from ovine IGH and TCRD loci were co-
amplified. In 24 of these 80 cells derived from paraffin sec-
tions, amplification gave rise to a PCR product for human
DNA, whereas not a single sheep-specific PCR product
was detected (Table II). Conversely, coamplification of hu-
man and ovine DNA fragments from cells micromanipu-
lated from chimeric tissue, which did not stain for human
proteins, only yielded PCR products of ovine but not hu-
man DNA (Table II). Using 16 PCR reactions, to which
only PCR buffer but no cells were added as negative con-
trols, neither human nor ovine DNA could be amplified.
We conclude that fusion events, if they occur at all under
physiological noninjury conditions, at best could account at
a very low frequency for the differentiated liver cell–spe-
cific phenotype of the USSC-derived hepatocytes inte-
grated into the chimeric liver tissue.
Discussion
In this study, an adherent CD45-negative unrestricted
stem cell population from human placental CB was shown
to be pluripotent. In contrast to other data from CB identi-
fying mesenchymal cells that differentiated only into osteo-
blasts, chondrocytes, adipocytes (39, 40), or neural progen-
Table II. Summary of Single Cell PCR Analysis of Micromanipulated Cells Revealing Complete Absence of Cell Fusion Events in This 
Noninjury Model
Gene locus Tissue Staining Positive cells Buffer controls 
Human VH1 Human Positive 8/24
Human VH1 Chimera Negative 0/24
Human VH1 Chimera Positive 22/80 0/16
Human TCRV7.2 Human Positive 8/24
Human TCRV7.2 Chimera Negative 0/24
Human TCRV7.2 Chimera Positive 21/80 0/16
 Human Positive 8/24
Human VH1 or TCRV7.2 Chimera Negative 0/24
Chimera Positive 24/80 0/16
Ovine VH7 Human Positive 0/24
Ovine VH7 Chimera Negative 9/24
Ovine VH7 Chimera Positive  0/80 0/16
Ovine TCRC
 Human Positive 0/24
Ovine TCRC
 Chimera Negative 9/24
Ovine TCRC
 Chimera Positive 0/80 0/16
 Human Positive 0/24
Ovine VH7 or TCRC
 Chimera Negative 9/24
Chimera Positive 0/80 0/16
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itors in vitro (41), this is the first time that an adherent cell
population has been identified, which after ex vivo expan-
sion allows directed differentiation into bone, cartilage, he-
matopoietic cells, neural, liver, and heart tissue in vivo in
various animal models. Previously, even the existence of
mesenchymal/mesodermal cells in term CB has been very
controversial. Several groups were unable to generate
MSCs (42, 43) or generated MSCs only in a limited num-
ber of CB specimens (39, 41). Although the USSCs de-
scribed here have a very low primary frequency in CB,
they can be expanded to at least 1015 cells and maintain a
normal karyotype. In contrast to MSCs from BM (26), the
USSCs have a wider differentiation potential and differ in
immunophenotype (44) and in their mRNA expression
profile. Further differences between MSCs and USSCs in-
clude absent expression in USSCs of CD50, CD62L,
CD106, and HAS1 (45), all of which are present in MSC.
In contrast, USSCs are positive for the epithelial markers
cytokeratin 8 and 18 and the endothelial marker KDR. In
addition, CD44 was expressed in USSCs but not found on
human or rodent MAPCs (12, 13). One major biological
difference between USSCs and human MAPCs generated
from BM (13) is the ease of generation of USSCs in cyto-
kine-free cultures. The potential to generate hematopoietic
cells as shown here from USSCs in vitro and in vivo has
not been described for human MAPC. The USSC popula-
tion can differentiate in vitro into osteoblasts, chondro-
blasts, adipocytes, and neural cell types in a homogeneous
fashion. In these in vitro experiments with a clear, directed
differentiation in the initial absence of the target tissue, cell
fusion cannot account for the observed differentiation
events. Osteogeneic, chondrogeneic, and neural differenti-
ation were documented in vivo and in vitro; however, as
shown for neuronal in vitro differentiation, only a precur-
sor-like phenotype was generated which might be ex-
plained by the lack of a proper microenvironment with
special cytokines and/or molecular signals which are not
present in the in vitro culture system. Thus, these specific
biological niches are able to fully exploit the intrinsic pluri-
potentiality of USSCs. Also, the in vivo differentiation of
hematopoietic cells, which is seen in a similar quantity as
that observed for purified CD34 from CB (46), could not
be confirmed in all experiments in vitro. However, a low
frequency of hematopoietic colonies in 2 out of 14 culture
experiments with cytokine-primed USSCs was observed.
The reason for this in vitro versus in vivo difference cannot
be explained yet. The immature mesodermal nature of
these cells could be one possible reason: this means that a
hematopoietic precursor cell derived from USSCs requires
different growth/differentiation conditions, which are pres-
ent in the in utero fetal sheep model (19).
One major difference compared to human MSCs is the
distribution of USSC-derived cells in the heart. In previous
studies using the preimmune fetal sheep model, we have
shown that human MSCs engraft predominantly in the
Purkinje fiber system and there are very few ventricular or
atrial cardiomyocytes of human origin (30). In contrast,
USSC-derived cells form both Purkinje fiber cells and car-
diomyocytes. This would indicate that the USSCs are of an
earlier cell type than multipotent MSC, possibly represent-
ing also the precursor cell for MSC. The ability of the
USSCs to form more than one cell type suggests that these
cells may be a valuable source of cells for the repair of the
infarcted heart. Future studies will address whether USSCs
engraft in other cell types in the heart. Another interesting
observation is that the engrafted USSCs, which differenti-
ated into cardiomyocytes, are interspersed with the sheep
cardiomyocytes and are thus likely to participate in myo-
cardial function. However similar to the engraftment of
human MSCs (30) into the Purkinje fiber system, USSC-
derived human cells form aggregates. This could indicate
that during fetal development there are different mecha-
nisms of expansion and/or recruitment of cells in the fe-
tus between ventricular or atrial cardiomyocytes and the
Purkinje fiber system. Given the remarkably high fre-
quency of human cells in the noninjury transplant model, it
was critical to determine whether any of the further differ-
entiation pathways of USSCs into hematopoietic cells, pa-
renchymal liver cells (	20%), and cardiomyocytes could be
a result of cell fusion events. Fused cells have been de-
scribed in the liver and in models of severe injury where
the mouse will die if there is not a significant degree of re-
generation (11). Because the human sheep chimeric model
is a noninjury model, no driving force for potential fusion
would exist apriori. As shown recently by Alvarez-Dolado
et al. (47) in a noninjury mouse model using the Cre/lox
system after BM transplantation, the frequency of newly
generated tissue-specific cells in brain, heart, and liver re-
sulting from fusion with respective tissue-specific cells after
10 mo at maximum was only 2.95 fused cells per section in
the liver and 2.84 fused cells per section in the heart, re-
spectively. This low frequency would hardly justify attrib-
uting fusion as the major or principal mechanism for the de
novo generation of organ-specific cells. In contrast, in ana-
lyzing fusion versus nonfusion events the data shown here
applying the noninjury in utero sheep model document a
substantial degree of USSC-differentiated human paren-
chymal liver cells/slide in the liver and the heart. In the
chimeric sheep liver, no indication of cell fusion was de-
tectable. Therefore, the de novo generation of liver and
heart cells from certain immature somatic progenitors ap-
pear predominantly engaged in noninjury organ regenera-
tion. Importantly, the application of USSCs into different
species thus far has not induced macroscopic or micro-
scopic tumors month or even years (in sheep) after trans-
plantation. In addition, USSCs lack HLA class II and co-
stimulatory molecule expression. Preliminary experiments
such as mixed culture inhibition suggest that USSCs, simi-
lar to adult and fetal MSCs (48), are also nonimmunoge-
neic and could even be immunosuppressive. This issue is
under further investigation.
Thus, on the basis of their pluripotency and expansion
under GMP conditions into large quantities, these USSC,
when pretested for infectious agents and matched for the
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major transplantation antigens, may serve as a universal al-
logeneic stem cell source for the future development of
cellular therapy for tissue repair and tissue regeneration.
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